Showing posts with label Drug Device Combination Products Market. Show all posts
Showing posts with label Drug Device Combination Products Market. Show all posts

Tuesday, 13 December 2016

North America Drug Device Combination Products Market Revenue by 2019

The global drug device combination products market is a consolidated one with a few well-entrenched companies dominating it. The competition in the market is predicted to heat up further in the near future on account of players channelizing their energies into research and development of products with innovative technologies and improved functionality. The players are also competing with each other to capture the under-penetrated emerging economies. Stringent regulatory norms also induces competition among manufacturers to introduce their products first.

The key players dominating the market are Abbott Laboratories, Inc., Allergan, Inc., Boston Scientific Corporation, CareFusion Corporation and Medtronic, Inc. Abbott Laboratories has enhanced its global presence so far through maximizing business through collaborations and acquisitions and by augmenting its product offerings. Allergan has invested heavily in research and development to come up with innovative products. Boston Scientific has resorted to acquisitions again to strengthen its position.

The global market for drug device combination products was worth US$87.1 bn in 2015 and it is predicted to be worth US$115.1 bn in 2019.

Download Complete Healthcare Industry Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1534

Underserved Asia Pacific to be the Engine for Growth

Based upon the type, the global drug device combination products can be segmented into infusion pumps, drug eluting stents, orthopedic combination products, transdermal patches, photosensitizers, wound care combination products, inhalers, intraocular implants, and drug eluting beads. Among them, the inhalers segment dominates the market with the maximum revenue. Going forward, it is expected to retain its dominant share in the market. It revenue in 2015 was US$32.5 bn. The market for transdermal patches followed next.

Geography-wise, North America has surpassed all other regions in terms of revenue generation year-on-year. In the upcoming years, it is predicted to maintain its leading position to reach a value of US$47.6% by 2019, even though it would pare some of its market share in terms of revenue. Europe stands second in terms of revenue generation. However, Asia Pacific is anticipated to steal the show by outshining all other regions. Its market is underpinned by numerous patients seeking treatment for cardiovascular diseases, diabetes, asthma, and obesity management. The drug device combination products market in emerging economies of the Middle East, Latin America and Africa will also enhance the growth in the market.

Growing Elderly Population at the Forefront of Driving Demand

A rising geriatric population at a heightened risk of having cardiovascular diseases, obesity, bone related disorders, various diabetes related disorders, and cancer, is at the forefront of driving growth in the global market for drug device combination products. Such people often suffer from severe fractures and hence require fracture risk assessment before the fracture happens. This is slated to fuel the market growth substantially. Another factor bringing about the growth is the increasing demand for minimally invasive surgeries. Explains the lead analyst of the report, “Minimally invasive surgeries suit the patient’s preferences due to the factors such as reduced post-surgical complications and side effects along with shorter patient recovery span and minimal pain. Therefore, the fact that interventional cardiology involving the implantation of stents and intraocular lenses is a minimally invasive procedure is proving to be a growth driver.”

One factor said to be countering the market’s growth is infections resulting from drug device combination products such as implants and associated product recalls. According to the analyst of the report, “Drug device combination products constantly face threats like product recalls owing to device malfunctions and side effects. Such attributes cause significant revenue losses for the manufacturers and thereby restrain the growth of the market.”

This review is based on the findings of a TMR report titled “Drug Device Combination Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013–2019.”

Browse Full Research on Drug Device Combination Products Market:
http://www.transparencymarketresearch.com/drug-device-combination.html

Wednesday, 27 August 2014

Drug Device Combination Products Market is Expected to ReachUSD 115.1 Billion Globally in 2019: TMR

According to a new market report published by Transparency Market Research “Drug Device Combination Products Market (Drug Eluting Stents, Infusion Pumps, Photosensitizers, Orthopedic Combination Products, Wound Care Combination Products, Inhalers, Transdermal Patches, Intraocular Implants and Drug Eluting Beads)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” the global drug device combination productsmarket was valued at USD 66.0 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115.1 billion in 2019.

Browse the full Drug Device Combination Products Market Report at http://www.transparencymarketresearch.com/drug-device-combination.html

Drug device combination products are therapeutic products that combine a drug and a medical device chemically and/or physically, to beproduced as a single product. These products can be designed for local as well as systemic drug delivery.With the advances in medical technology, medical devices have changed their definition to more complex devices which assist in improving the efficiency of drugs in therapeutic treatments. These innovations have also made it difficult for regulatory agencies to classify and provide guidelines for safety and validation of these products.Newer developments in drug device combination products have yielded several products for targeted drug delivery within the body. Clinical trials for drug device combination products are more comprehensive and expensive coupled with complications as compared to those required for individual drug and device.

Growing elderly population combined with rise in risk for cardiovascular diseases, asthma and various other chronic disorders contribute to the growth of this market particularly in emerging economies of Middle East, India and China. Moreover, technological advancessuch as biodegradable implants coupled with increase in access and recognition of these technologies in emerging market, will serve as an opportunity for investors to invest in.

The global market for drug device combination products has been studied from the perspective of current widely used various product types.The report provides a detailed analysis of drug eluting stents which are segmented into coronary stents and peripheral vascular stents while the infusion pumps include implantable infusion pumps and ambulatory infusion pumps. Inhalers include metered dose inhalers, dry powder inhalers and nebulizers. The others segment comprises intraocular implants and drug eluting beads. The market estimations for transdermal patches, orthopedic combination products such as bone graft implants and antibiotic loaded bone cements, wound care combination products and photosensitizers have also been provided in the report for the forecast period 2013-2019.

The overall market for drug device combination products is fragmented owing to number of small players involved in respective product segments. In 2012, transdermal patches accounted for the largest share by revenue at USD 25.1 billion of the total drug device combination products market. However, due to the product recalls and consequent stringent regulatory approval procedures, the overall market revenue is expected to decline during the forecast period in the U.S and Europe.The market for inhalers accounted for the second largest share at over USD 20billion in 2012. It is estimated that the global market for inhalers will grow at a CAGR of over 8% from 2013 to 2019, owing to its high incidence rates of asthmatic and chronic obstructive pulmonary disease (COPD) patients.

Geographically, North America dominatedthe global market for drug device combination products in terms of revenue generation and is expected to maintain its position throughout the forecast period. Theadoption of drug eluting stents, implants, growing elderly population and rise in incidences of hypertension and obesity in the U.S., is expected to contribute to the leadership of the North American market. Europe was the second largest regional market for drug device combination productsin 2012, owing to the increased demand for drug eluting stents and infusion pumps.

The global drug device combination products market is dominated by few major players includingBoston Scientific Corporation, Medtronic, Inc., Abbott Laboratories, Inc., CareFusion Corporation and Allergen, Inc.



The global drug device combination products marketis segmented as follows:

Drug Device Combination ProductsMarket, by Product Type
§     Drug Eluting Stents
o     Coronary Stents
o     Peripheral Vascular Stents
§     Infusion Pumps
o     Implantable Infusion Pumps
o     Ambulatory Infusion Pumps
§     Photosensitizers
§     Orthopedic Combination Products
o     Bone Graft Implants
o     Antibiotic Loaded Bone Cement
§     Wound Care Combination Products
§     Inhalers
o     Metered Dose Inhalers
o     Dry Powder Inhalers
o     Nebulizers
§     Transdermal Patches
§     Others
o     Intraocular Implants
o     Drug Eluting Beads
Drug Device Combination Products, by Geography
·        North America
·        Europe
·        Asia-Pacific
·        Rest of the World (RoW)


About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/